The latest price target for Checkpoint Therapeutics (NASDAQ:CKPT) was reported by HC Wainwright & Co. on November 14, 2024. The analyst firm set a price target for $20.00 expecting CKPT to rise to within 12 months (a possible 461.80% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Checkpoint Therapeutics (NASDAQ:CKPT) was provided by HC Wainwright & Co., and Checkpoint Therapeutics reiterated their buy rating.

There is no last upgrade for Checkpoint Therapeutics

There is no last downgrade for Checkpoint Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Checkpoint Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Checkpoint Therapeutics was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Checkpoint Therapeutics (CKPT) rating was a reiterated with a price target of $20.00 to $20.00. The current price Checkpoint Therapeutics (CKPT) is trading at is $3.56, which is out of the analyst’s predicted range.